Bristol-Myers Squibb: Lupus Erythematosus, Systemic trials

The registry lists 22 Lupus Erythematosus, Systemic studies with Bristol-Myers Squibb as lead sponsor. 5 are open to participants now and 8 have results posted.

Phase 1 8Phase 2 9Phase 3 4Phase 4 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of BMS-986553 in Participants With Refractory Autoimmune DiseasesNot yet recruitingNCT07873931Phase 1
• Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study CompletersNot yet recruitingNCT07791199Phase 3
• A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 ImmunosuppressantsRecruitingNCT07175285
• A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune DiseasesRecruitingNCT07115745Phase 1
• A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132RecruitingNCT06875960Phase 4
• Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid ArthritisCompletedNCT04186871Phase 2Results posted
• Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus ErythematosusCompletedNCT03920267Phase 2Results posted
• An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus ErythematosusCompletedNCT03252587Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus ErythematosusCompletedNCT03161483Phase 2Results posted
• Safety and Efficacy Study of a Biologic to Treat Systemic Lupus ErythematosusCompletedNCT02265744Phase 2Results posted
• A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.CompletedNCT02185040Phase 2Results posted
• Efficacy and Safety Study of Abatacept to Treat Lupus NephritisTerminatedNCT00430677Phase 2/3Results posted
• Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With PrednisoneCompletedNCT00119678Phase 2Results posted
• A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)Active, not recruitingNCT07015983Phase 2
• A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of LupusCompletedNCT06013995Phase 1
• A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)Active, not recruitingNCT05869955Phase 1
• A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus ErythematosusActive, not recruitingNCT05620407Phase 3
• A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)Active, not recruitingNCT05617677Phase 3
• A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus ErythematosusCompletedNCT04493541Phase 1
• An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram EffectsCompletedNCT03541564Phase 1
• The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female PatientsCompletedNCT03262727Phase 1
• A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet FormulationCompletedNCT03254784Phase 1